(Q33608191)

English

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

23

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

B J Monk

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

M F Brady

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

C Aghajanian

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

H A Lankes

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

T Rizack

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

J Leach

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

J M Fowler

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

R Higgins

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

P Hanjani

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

M Morgan

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

R Edwards

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

W Bradley

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

T Kolevska

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

P Foukas

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

E M Swisher

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

K S Anderson

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

R Gottardo

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

J K Bryan

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

M Newkirk

19

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

K L Manjarrez

20

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

R S Mannel

21

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

R M Hershberg

22

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

1 May 2017

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

28

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

996-1004

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Mutational heterogeneity in cancer and the search for new cancer-associated genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Latest research and treatment of advanced-stage epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Coordinated regulation of myeloid cells by tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Calreticulin exposure dictates the immunogenicity of cancer cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Inst

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5406764

21 June 2018

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX049

21 January 2018

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX049

21 January 2018

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX049

21 January 2018

Targeting Programmed Cell Death 1 in Ovarian Cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX049

21 January 2018

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28453702

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDX049

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28453702%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33608191&oldid=1541447452"